Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
The Pfizer‐BioNTech mRNA vaccine (BNT162b2) is an effective and well‐tolerated coronavirus disease 2019 (COVID‐19) vaccine. However, rare adverse events have been reported. We report two cases of COVID‐19 mRNA vaccine‐related interstitial... more
The Pfizer‐BioNTech mRNA vaccine (BNT162b2) is an effective and well‐tolerated coronavirus disease 2019 (COVID‐19) vaccine. However, rare adverse events have been reported. We report two cases of COVID‐19 mRNA vaccine‐related interstitial lung disease (ILD). A 67‐year‐old man and a 70‐year‐old man with underlying ILD presented to our hospital with a few days of fever and respiratory symptoms after receiving the BNT162b2 vaccine. Drug‐related pneumonitis due to the COVID‐19 mRNA vaccine was diagnosed. One case was diagnosed with lymphocytic alveolitis by bronchoalveolar lavage fluid and transbronchial lung cryobiopsy. Both patients were successfully treated with corticosteroids, and they attended outpatient clinics thereafter. Although the safety and efficacy of COVID‐19 vaccines have been established, further studies are needed to estimate long‐term data and reports of rare adverse reactions. We present the clinical course of two cases, review previously published case reports on COVID‐19 mRNA vaccine‐related ILD and discuss the relevant findings.
Research Interests:
Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) in patients with COVID-19 varies, as well as their risks of mortality. The present study aimed to assess the prevalence of... more
Introduction The prevalence of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) in patients with COVID-19 varies, as well as their risks of mortality. The present study aimed to assess the prevalence of asthma, COPD, and ACO as comorbidities, and to determine their risks of mortality in patients with COVID-19 using a systematic review and meta-analysis. Methods We systematically reviewed clinical studies that reported the comorbidities of asthma, COPD, and ACO in patients with COVID-19. We searched various databases including PubMed (from inception to 27 September 2021) for eligible studies written in English. A meta-analysis was performed using the random-effect model for measuring the prevalence of asthma, COPD, and ACO as comorbidities, and the mortality risk of asthma, COPD, and ACO in patients with COVID-19 was estimated. A stratified analysis was conducted according to country. Results One hundred one studies were eligible, and 1,229,434 pati...
Research Interests:
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure that uses thermal energy to reduce airway smooth muscle and prevent chronic structural changes of asthmatic patients. BT was reported to improve asthma-related quality of... more
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure that uses thermal energy to reduce airway smooth muscle and prevent chronic structural changes of asthmatic patients. BT was reported to improve asthma-related quality of life (QOL), suppress asthma exacerbation, and maintain pulmonary function for 5 years. However, the detailed changes in pulmonary function after BT are not well known. We aimed to clarify the changes in pulmonary function after BT treatment in severe asthma patients. Methods: We prospectively included uncontrolled severe asthma patients who underwent BT treatment at our institution since BT was available in 2015. We analyzed the measured parameters on pulmonary function test, pulmonary impedance, and the fraction of exhaled nitric oxide (FeNO) levels in these patients. All patients completed 3 times of BT treatment. Baseline functions were taken within one month prior to the first BT; post-treatment functions were examined one month after the third BT procedure. Results: There were 9 severely asthmatic patients, with mean age of 55.7 years and disease duration of 27.6 years, on GINA treatment Step 5; exacerbation rate was 6.7 times/year. QOL and asthma control scores improved in almost all of the patients. FEV 1 increased by 18%; the increases in the values of V75, V50, and MMF were 29%, 63%, and 46%, respectively. There were no changes in RV, FRC, and TLC. Respiratory resistance and respiratory reactance improved in 5 patients and 4 patients, respectively. A decrease of FeNO levels was observed in only 4 patients. Conclusion: BT improved symptoms, QOL, and pulmonary function, including V50, MMF, V75, and FEV 1 , in severely asthmatic patients.
Research Interests:
Research Interests:
Research Interests:
Research Interests:
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI,... more
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
Research Interests:
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI,... more
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
Research Interests:
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the... more
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the abrupt onset of hemoptysis. The diagnosis of DPL was confirmed by surgical lung biopsy and lymphangiography. Histopathological investigation showed dilated vascular and lymphatic vessels. DPL can cause acute and life-threatening symptoms during its chronic clinical course. A coexisting anomaly in the venous system may be present in DPL patients with hemoptysis.
Research Interests:
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the... more
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the abrupt onset of hemoptysis. The diagnosis of DPL was confirmed by surgical lung biopsy and lymphangiography. Histopathological investigation showed dilated vascular and lymphatic vessels. DPL can cause acute and life-threatening symptoms during its chronic clinical course. A coexisting anomaly in the venous system may be present in DPL patients with hemoptysis.
Research Interests:
Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De Nolf for his expertise in analyzing public scRNASeq datasets. We are thankful to prof. David Ron for providing us with critical reagents. The... more
Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De Nolf for his expertise in analyzing public scRNASeq datasets. We are thankful to prof. David Ron for providing us with critical reagents. The SJ laboratory is supported by an ERC Consolidator Grant (DCRIDDLE819314), FWO program grants (G017521N and G063218N), and an EOS grant (G0G7318N). The BNL laboratory is supported by ERC Advanced Grant, a concerted research initiative grant (GOA) from Ghent University (01G02817), and an EOS research grant. During this work, EC was supported by a FWO personal fellowship (11Z5615N). ND is supported by personal fellowships from FWO (11Y8417N and 1258921N).
Research Interests:
Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De Nolf for his expertise in analyzing public scRNASeq datasets. We are thankful to prof. David Ron for providing us with critical reagents. The... more
Gert Van Isterdael, Julie Van Duyse, and Kelly Lemeire for extensive training. We thank Clint De Nolf for his expertise in analyzing public scRNASeq datasets. We are thankful to prof. David Ron for providing us with critical reagents. The SJ laboratory is supported by an ERC Consolidator Grant (DCRIDDLE819314), FWO program grants (G017521N and G063218N), and an EOS grant (G0G7318N). The BNL laboratory is supported by ERC Advanced Grant, a concerted research initiative grant (GOA) from Ghent University (01G02817), and an EOS research grant. During this work, EC was supported by a FWO personal fellowship (11Z5615N). ND is supported by personal fellowships from FWO (11Y8417N and 1258921N).
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Introduction Bronchial thermoplasty (BT) is a bronchoscopic procedure that involves the delivery of thermal radiofrequency energy to the bronchial wall for treating severe asthma. It has been suggested that too many radiofrequency... more
Introduction Bronchial thermoplasty (BT) is a bronchoscopic procedure that involves the delivery of thermal radiofrequency energy to the bronchial wall for treating severe asthma. It has been suggested that too many radiofrequency activations could induce serious adverse events (SAEs) at an early stage. We aimed to examine the number of radiofrequency activations at each session and early lung function changes from baseline to determine whether these are related to SAEs. Methods We retrospectively investigated 13 consecutive patients who underwent three sessions each of BT for severe asthma from February 2015 to January 2016. Lung function tests were performed on the day before and after each BT procedure. Since we compared the number of activations and lung function changes from baseline after each session, a total of 39 sessions were reviewed. The relationship between the number of radiofrequency activations and each lung function change from baseline was also examined by linear r...
Research Interests:
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI,... more
CLINICAL INVESTIGATION FOR THE EFFICACY OF PULSE OXI-CAPNOMETER“CAPNO-EYE”IN RESPIRATORY FAILURE PATIENTS-COMPARISON BETWEEN PACO2, PVCO2, PTCCO2 AND ETCO2 SHOTA FUJIMOTO, MANABU SUZUKI, RITSU IBUSUKI, KENTARO TAMURA, SACHI MATSUBAYASHI, NAOKO NAGANO, YOSHIE TSUJIMOTO, TAMAKI KAKUWA, TOMOYUKI SUZUKI, KEITA SAKAMOTO, AYAKO SHIOZAWA, KONOMI KOBAYASHI, SHOTA YAMAMOTO, ERIKO MIYAWAKI, MASAO HASHIMOTO, SATORU ISHII, ERIKO MORINO, JIN TAKASAKI, GO NAKA, TERUHIKO SATO, MOTOYASU IIKURA, SHINYU IZUMI, YUICHIROU TAKEDA, HARUHITO SUGIYAMA Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
Research Interests:
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the... more
Diffuse pulmonary lymphangiomatosis (DPL) is a rare lymphatic disease that can cause diverse respiratory symptoms. A 22-year-old man, whose chest CT had shown an abnormality for years, presented with acute respiratory failure due to the abrupt onset of hemoptysis. The diagnosis of DPL was confirmed by surgical lung biopsy and lymphangiography. Histopathological investigation showed dilated vascular and lymphatic vessels. DPL can cause acute and life-threatening symptoms during its chronic clinical course. A coexisting anomaly in the venous system may be present in DPL patients with hemoptysis.
Research Interests:
Research Interests:
Introduction Bronchial thermoplasty (BT) is a bronchoscopic procedure that involves the delivery of thermal radiofrequency energy to the bronchial wall for treating severe asthma. It has been suggested that too many radiofrequency... more
Introduction Bronchial thermoplasty (BT) is a bronchoscopic procedure that involves the delivery of thermal radiofrequency energy to the bronchial wall for treating severe asthma. It has been suggested that too many radiofrequency activations could induce serious adverse events (SAEs) at an early stage. We aimed to examine the number of radiofrequency activations at each session and early lung function changes from baseline to determine whether these are related to SAEs. Methods We retrospectively investigated 13 consecutive patients who underwent three sessions each of BT for severe asthma from February 2015 to January 2016. Lung function tests were performed on the day before and after each BT procedure. Since we compared the number of activations and lung function changes from baseline after each session, a total of 39 sessions were reviewed. The relationship between the number of radiofrequency activations and each lung function change from baseline was also examined by linear r...
Research Interests:
Introduction Bronchial thermoplasty (BT) is a bronchoscopic procedure that involves the delivery of thermal radiofrequency energy to the bronchial wall for treating severe asthma. It has been suggested that too many radiofrequency... more
Introduction Bronchial thermoplasty (BT) is a bronchoscopic procedure that involves the delivery of thermal radiofrequency energy to the bronchial wall for treating severe asthma. It has been suggested that too many radiofrequency activations could induce serious adverse events (SAEs) at an early stage. We aimed to examine the number of radiofrequency activations at each session and early lung function changes from baseline to determine whether these are related to SAEs. Methods We retrospectively investigated 13 consecutive patients who underwent three sessions each of BT for severe asthma from February 2015 to January 2016. Lung function tests were performed on the day before and after each BT procedure. Since we compared the number of activations and lung function changes from baseline after each session, a total of 39 sessions were reviewed. The relationship between the number of radiofrequency activations and each lung function change from baseline was also examined by linear r...
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. However, 150 mg/day of erlotinib seems too toxic as maintenance... more
Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. However, 150 mg/day of erlotinib seems too toxic as maintenance therapy. This study aimed to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment after platinum doublet chemotherapy in NSCLC harboring epidermal growth factor receptor (EGFR) mutation. Activated EGFR-mutation-positive NSCLC patients who did not progress after first-line platinum-doublet chemotherapy, ≥20 and ≤85 years old, with performance status (PS) 0-3 were included in this study. Low-dose erlotinib (25 mg/day) was administered until disease progression. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), OS, and safety. The required sample size was 40 patients. The study was stopped early, after achieving only 28% of planned enrollment, due to poo...
Research Interests:
Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. However, 150 mg/day of erlotinib seems too toxic as maintenance... more
Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. However, 150 mg/day of erlotinib seems too toxic as maintenance therapy. This study aimed to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment after platinum doublet chemotherapy in NSCLC harboring epidermal growth factor receptor (EGFR) mutation. Activated EGFR-mutation-positive NSCLC patients who did not progress after first-line platinum-doublet chemotherapy, ≥20 and ≤85 years old, with performance status (PS) 0-3 were included in this study. Low-dose erlotinib (25 mg/day) was administered until disease progression. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), OS, and safety. The required sample size was 40 patients. The study was stopped early, after achieving only 28% of planned enrollment, due to poo...